Multi-center, Double-blind, Randomised, Placebo-controlled, Phase IIa Study to Investigate Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacogenomics of Multiple Intravenous Doses of BI 655130 in Patients With Palmoplantar Pustulosis (PPP)

Trial Profile

Multi-center, Double-blind, Randomised, Placebo-controlled, Phase IIa Study to Investigate Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacogenomics of Multiple Intravenous Doses of BI 655130 in Patients With Palmoplantar Pustulosis (PPP)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Aug 2018

At a glance

  • Drugs BI 655130 (Primary)
  • Indications Palmoplantar pustulosis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 17 Jul 2018 According to EudraCT record, this trial has been completed in Denmark.
    • 20 Mar 2018 Planned End Date changed from 24 Oct 2018 to 5 Nov 2018.
    • 20 Mar 2018 Planned primary completion date changed from 4 Jul 2018 to 9 Jul 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top